In an effort to improve the survival of cancer patients, new therapeutic approaches focusing
on the molecular mechanisms that mediate tumour cell growth or survival have gained much …

Objective Epidermal growth factor receptor (EGFR) mutations in lung adenocarcinoma are
involved in the tumorigenesis and regulation of cell metabolism via Akt signaling. F-18 …

Lung cancer is still the main cause of cancer-related deaths worldwide, with most patients
present with advanced disease and poor long-term prognosis. The aim of lung cancer …

American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy
for Stage IV Non–Small-Cell Lung Cancer | JCO Oncology Practice Skip to main content …

Small cell lung cancer (SCLC) is an aggressive form of lung cancer, which represents 13%
of all cases and is strongly associated with cigarette smoking. The survival of SCLC patients …

Aims: To assess healthcare costs during treatment with epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors (TKIs) and following disease progression in patients with …

In a series of more than 500 non–small-cell lung cancer (NSCLC) patients evaluated by
Cella and colleagues in quality of life studies, the prevalence of poor performance status …

Background Many targeted therapies used in the treatment of cancer can lead to the
development of xerosis, but the incidence and relative risk of xerosis have not been …

The EGFR pathway has emerged as a key target in non-small-cell lung cancer. EGF
receptor (EGFR) inhibition in non-small-cell lung cancer is achieved via small molecular …

As our understanding of HNSCC increases so has biomarker development. HPV16
integration is a significant marker of favorable prognosis and response to therapy for …